XCH
XCHG Limited
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeXCHG rebounded sharply with 61% Q3 YoY revenue growth after a disastrous H1 2026 (-49% revenue, widened losses), and is pursuing aggressive capital structure changes including a 20x increase in Class B voting rights ahead of a December 4 shareholder vote. However, the company faces significant headwinds: H1 results were materially weak, analyst downgrades are active, stock volatility and trading halts have persisted, and governance concentration moves raise corporate governance concerns.
Red flags
- •H1 2026 revenue collapsed 49% YoY to $10.27M with net loss widening to $11.1M vs. $7.3M prior year
- •Nasdaq compliance issue requiring September 2026 restatement of minimum bid price compliance
- •Analyst downgrade with $2.00 price target implying 52.6% downside as of mid-October 2026
- •Multiple trading halts (October 20 for volatility, November 2-3 for news-pending)
- •Proposed governance change to increase Class B voting rights from 10 to 200 votes per share raises control concentration and shareholder protection concerns
- •Management instability with President reassignment and board reshuffle in September-October 2026
- •Q3 recovery growth rate (61% YoY) insufficient to offset H1 magnitude of decline and does not restore to prior baseline
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Citadel Advisors | SC 13G/A | −214.3M | 2.1% | -16.8% vs SPY -20.0% abs | 2026-11-16 | ↗ |
| Citadel Advisors | SC 13G | NEW | 9.7% | -17.0% vs SPY -19.2% abs | 2026-08-14 | ↗ |